Epigenetic editing and therapeutic approaches to autism

Epigenetic editing and therapeutic approaches to autism

Begin Time:


End Time:



Epigenetic editing and therapeutic approaches to autism

Date and Time : 

22 November 2022, 10:00-11:00pm

Room A203-1, ZJE building 


Zoom:833 0831 3045



Prof. Rudolf Jaenisch

Founding Member, Whitehead Institute

Professor of Biology, MIT, Department of Biology

Host: Dr. Di Chen

Rudolf Jaenisch,美国科学院院士,麻省理工学院怀特黑德生物医学研究所教授,干细胞研究领域的权威人物,研究做出第一只转基因小鼠。他是怀特黑德研究所的创始人之一,曾经担任过国际干细胞学会的主席。其在一系列的领域做出了有影响的工作,包括基因敲除小鼠、表观遗传学研究、核移植、iPS等。

Jaenisch, a Whitehead Founding Member, focuses on understanding epigenetic regulation of gene expression. He is a pioneer in the study of cellular reprogramming, the process of converting adult cells into induced pluripotent stem (iPS) cells. 


Jaenisch’s lab was the first to create a transgenic animal model using SV40 and retroviruses. He has been the first to conduct an experiment showing that therapeutic cloning could correct genetic defects in mice. He is currently using patient-derived iPS cells to develop sophisticated models for the study of cancer, diabetes, and neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Jaenisch is working with human stem cells to study disease risk factors. 


Jaenisch’s discoveries forever changed the landscape of how biological science is conducted. His methodological breakthroughs allow scientists, for the first time, to study human brain functions in normal and pathological conditions in its full complexity of all brain cell types. His stellar scientific acumen will be focused in partnership with Rick Young on condensate biology advancing research in cancer and neurodegenerative disease.